Research regarding GHRP 2 involve addressing growth hormone deficiency. When combined with a growth hormone receptor, GHRP 2 is considered a synthetic agonist of ghrelin, which causes a physiological response. In the case of GHRP 2, it promotes growth hormone secretion, making it a novel growth hormone secretagogue.
The acronym GHRP means “growth hormone-releasing peptide.” GHRP 2 is known by several names in the pharmaceutical world, the most common of which is pralmorelin, which is much easier to remember and pronounce than pralmorelin hydrochloride or pralmorelin dihydrochloride.
GHRP 2 has been extensively studied for its ability to aid in growth hormone secretion as well as appetite and food consumption because it can bind to growth hormone secretagogue receptors. The synthetic peptide comprises six amino acids and is a non-glycosylated polypeptide, meaning it does not bind to glycans or proteins.
GHRP 2 belongs to a class of growth hormone-releasing peptides that are still undergoing clinical trials. For this very fact, purchasing GHRP 2 should only be for the sole purpose of research and not for human consumption.